Vironix remote physiological monitoring & disease-specific AI intelligence for respiratory and cardiovascular chronic illnesses
Either you or someone you know has been impacted by heart or lung disease.
17.9 MILLION PEOPLE
die each year from cardiovascular disease.
That’s one death every 56 seconds.
People diagnosed with or at risk of heart failure, COPD, asthma, & acute respiratory illness face constant risk of death, hospitalization, massive healthcare expenditures, and persistent anxiety. If detected and managed early, singular health deterioration episodes, which include exacerbations & infections, can be readily addressed at home with diet, medications, and rest.
is the cost of preventable heart and lung disease to employers and health insurance providers
Peer-Reviewed, World Class R&D
Clinically validated algorithms built by scientists and clinicians.
Vironix Health Presentation at Prestigious Machine Learning for Healthcare Symposium 2023
We’re delighted that Vironix Health’s paper titled “ScoEHR: Generating Synthetic Electronic Health Records using Continuous-time Diffusion Models” was a featured presentation at the Machine Learning for Healthcare Conference last week in New York City.
Vironix Health and University of Oxford are conducting breakthrough research
Vironix Health and University of Oxford are conducting breakthrough research on using predictive models for early identification of patients who require intensive management of chronic kidney disease (CKD).
Vironix Health Secures New Capital Investors
Vironix successfully secured new capital commitments through a seed round extension convertible note at the prestigious Invest Wealth Summit 2023.
Vironix was formed by passionate scientists, physicians, technologists, and entrepreneurs who have amassed decades of research, development, and commercialization expertise in the development, testing, and commercialization of medical technology.